Sign In
Buy GNPX
$4.04
-0.390 (-8.80%)
At Close: Nov 17, 2025
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
07:00am, Tuesday, 18'th Nov 2025
Strengthens Intellectual Property Portfolio and Provides Protection for Therapeutic Combination in Acclaim-3 Clinical Trial AUSTIN, Texas , Nov. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or th
Adds to the Previously Granted Patents Covering the Use of REQORSA in Combination with Immune Checkpoint Inhibitors Strengthens Patent Estate and Provides Additional Protection in Large Market AUSTIN,
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
11:19am, Tuesday, 28'th Oct 2025
$3.4 million upfront with up to an additional $6.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants AUSTIN, Texas , Oct. 28, 2025 /PRNewswire/ -- Genprex,
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Combining REQORSA with Alectinib Further Increased Apoptosis and Improved Treatment Outcom
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
08:12am, Thursday, 23'rd Oct 2025
$2.7 million upfront with up to an additional $5.4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants AUSTIN, Texas , Oct. 23, 2025 /PRNewswire/ -- Genprex,
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Research Suggests that REQORSA May Be an Effective Treatment in Patients Progressing on Al
Reqorsa® Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer AUSTIN, Texas , Oct. 14, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
08:30am, Tuesday, 02'nd Sep 2025
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 2, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stag
Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas , Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
08:30am, Monday, 04'th Aug 2025
Company Achieves Multiple Clinical Development Milestones in 2025 Patient Treatment Continues in Two Lung Cancer Clinical Trials AUSTIN, Texas , Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" o
Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas , June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNP
Novel Diabetes Gene Therapy Shows Potential for Re-Dosing Using Non-Viral Delivery System AUSTIN, Texas , June 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a cl
Genprex to Participate at BIO 2025 International Convention
07:00am, Tuesday, 03'rd Jun 2025
AUSTIN, Texas , June 3, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient
Presentation to Highlight Genprex's Study of Reqorsa® Gene Therapy in Combination with Tecentriq® for the Treatment of Extensive Stage Small Cell Lung Cancer AUSTIN, Texas , May 29, 2025 /PRNewswire
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
07:00am, Wednesday, 28'th May 2025
Novel Gene Therapy is Addressing Both Type 1 and Type 2 Diabetes AUSTIN, Texas , May 28, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy
